Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis


Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.

Phase 1 trial data showed promising results with 79% of patients achieving SVR35 and an average Abs-TSS improvement of 18.5 points at week 24 when combining selinexor with ruxolitinib, compared to historical data showing less than 50% SVR35 achievement with JAK inhibitor monotherapy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
1
Translate
Report
1368 Views
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2299Followers
104Following
23KVisitors
Follow